亞諾法生技股份有限公司
亞諾法生技股份有限公司（Abnova (Taiwan) Corporation）研發製造抗體、蛋白質及體外診斷試劑。產品組合包括新冠肺炎檢測、 Ab 配對組件及循環罕見細胞分析。亦提供基因合成及胜肽服務。公司成立於 2002 年，總部位於台灣台北。
該股 RSI(6) 為 38.2，處於中性區間，短線無明顯超買超賣訊號。股價跌破5日、20日、60日、120日均線。KD 指標中性（K=32.9）；MACD 柱狀體為負值，空方動能持續。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 08-12 | -8 | 0 | 0 | -8 |
| 08-11 | -11 | 0 | -5 | -16 |
| 08-10 | -1 | 0 | 0 | -1 |
| 08-07 | +10 | 0 | 0 | +10 |
| 08-06 | -50 | 0 | -1 | -51 |
| 08-05 | +102 | 0 | 0 | +102 |
| 08-04 | +38 | 0 | -14 | +24 |
| 08-03 | -18 | 0 | -4 | -22 |
| 07-31 | +5 | 0 | +1 | +6 |
| 07-30 | +10 | 0 | +2 | +12 |
| 07-29 | +107 | 0 | +11 | +118 |
| 07-28 | -17 | 0 | 0 | -17 |
| 07-27 | +43 | 0 | +1 | +44 |
| 07-24 | -189 | 0 | 0 | -189 |
| 07-23 | -262 | 0 | +3 | -259 |
| 07-22 | +13 | 0 | 0 | +13 |
| 07-21 | +3 | 0 | -4 | -1 |
| 07-20 | -160 | 0 | -9 | -169 |
| 07-17 | +78 | 0 | +13 | +91 |
| 07-16 | +10 | 0 | 0 | +10 |
| 07-15 | +73 | 0 | 0 | +73 |
| 07-14 | -4 | 0 | +1 | -3 |
| 07-13 | +2 | 0 | +3 | +5 |
| 07-09 | -19 | 0 | -1 | -20 |
| 07-08 | -22 | 0 | 0 | -22 |
| 07-07 | -35 | 0 | 0 | -35 |
| 07-06 | +126 | 0 | 0 | +126 |
| 07-03 | +40 | 0 | 0 | +40 |
| 07-02 | +8 | 0 | 0 | +8 |
| 07-01 | +14 | 0 | 0 | +14 |
| 06-30 | -44 | 0 | +1 | -43 |
| 06-29 | +4 | 0 | 0 | +4 |
| 06-26 | -81 | 0 | -1 | -82 |
| 06-25 | -13 | 0 | 0 | -13 |
| 06-24 | +7 | 0 | 0 | +7 |
| 06-22 | -15 | 0 | -2 | -17 |
| 06-18 | +18 | 0 | +2 | +20 |
| 06-17 | +14 | 0 | 0 | +14 |
| 06-16 | -27 | 0 | 0 | -27 |
| 06-15 | +47 | 0 | 0 | +47 |
| 06-12 | +8 | 0 | 0 | +8 |
| 06-10 | -44 | 0 | -1 | -45 |
| 06-09 | -20 | 0 | 0 | -20 |
| 06-08 | -14 | 0 | 0 | -14 |
| 06-04 | +36 | 0 | 0 | +36 |
| 06-03 | +65 | 0 | 0 | +65 |
| 06-02 | +7 | 0 | 0 | +7 |
| 06-01 | -4 | 0 | 0 | -4 |
| 05-29 | +72 | 0 | -1 | +71 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/07 | 2631 萬 | -10.3% | -6.0% |
| 2026/06 | 2934 萬 | -1.8% | -6.4% |
| 2026/05 | 2989 萬 | +2.7% | +0.5% |
| 2026/04 | 2910 萬 | -15.4% | -4.6% |
| 2026/03 | 3440 萬 | +23.7% | -4.1% |
| 2026/02 | 2781 萬 | +8.2% | -12.4% |
| 2026/01 | 2570 萬 | -6.5% | +12.4% |
| 2025/12 | 2748 萬 | -7.3% | -3.0% |
| 2025/11 | 2964 萬 | +10.6% | -5.7% |
| 2025/10 | 2681 萬 | +3.3% | -5.2% |
| 2025/09 | 2595 萬 | -17.2% | -5.5% |
| 2025/08 | 3133 萬 | - | -5.3% |